Transition metal-ions based nanocomposites are widely used for their ease of synthesis and cost-effectiveness in sensor development. In this study, we have synthesized bi-metallic (iron and zinc) metal organic framework...

Herein, we report the preparation of a metal-chelate immobilized hydrophilic poly hydroxyethylmethacrylate-based monolith of 100 μL volume in a plastic syringe. The monolith is elastic in nature, contains well interconnected pores with a permeability (k) of 1.3 × 10 m . Immobilization of iminodiacetic acid (IDA) is performed via schiff base reaction. Adsortion of IgG on this copper-IDA monolith is of langmuir isotherm with a maximum adsorption capacity of ∼25 mg IgG per g monolith. IgG adsorption capacity of this affinity monolith remained unaffected with increase of flow rate. This proposed metal-chelate monolith in syringe format has the potential for application in proteomics.

No abstract

Penicillin discovery has put forward great expectations and hope for the treatment of several infectious diseases. Inappropriate and excess use of antibiotics has led to the emergence of antibiotic-resistant (AMR) worldwide, which has become one of the greatest threats to global health. However, in the late 1940s, after approval, mass production (lead to reduced cost) and supply (lead to easy access to all people) led to the emergence of Antimicrobial Resistance (AMR). A similar behavioral pattern ensued as other classes of antibiotics were discovered (through increasing utilization to resistance). Substandard infection control practices in public healthcare settings eased the spread and transmission of resistant organisms and intensified antimicrobials' effect. The healthcare community responded with two major programs – Infection Control in the 1980s and Antimicrobial Stewardship (in the last decade). These programs depend on the end-user; however, while the importance of such global control and prevention programs cannot be disputed, these efforts alone are insufficient against the advent of AMR. Also, drug discovery has suffered from a shortage of exploitable bacterial target sites, leading to the slow evolution of novel potent drugs.